Before the over-allotment option was exercised, Vigonvita Life Sciences raised $76 million in gross proceeds from the completion of its global offering and H-share listing on the Hong Kong Stock Exchange, resulting in a market capitalization of $720 million. The public offering in Hong Kong was 6,237 times oversubscribed.